Cannara Biotech Inc.
LOVFF
$0.926
-$0.0321-3.35%
OTC PK
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | 25.18% | 30.37% | 41.53% | 49.30% | 58.30% |
| Total Other Revenue | 121.15% | -87.92% | -92.40% | -138.78% | -129.78% |
| Total Revenue | 25.32% | 30.53% | 41.73% | 49.15% | 58.25% |
| Cost of Revenue | 25.13% | 54.14% | 71.39% | 79.22% | 70.46% |
| Gross Profit | 25.59% | 2.74% | 8.72% | 16.67% | 43.84% |
| SG&A Expenses | 20.39% | 43.09% | 43.96% | 41.27% | 46.05% |
| Depreciation & Amortization | 24.52% | 15.01% | 41.58% | -16.07% | -21.65% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.06% | 49.31% | 61.18% | 63.13% | 57.73% |
| Operating Income | 37.67% | -40.94% | -35.41% | -11.39% | 61.18% |
| Income Before Tax | 111.84% | -41.96% | -37.47% | 6.93% | 74.14% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 109.88% | -28.60% | -9.91% | 6.93% | 74.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 109.88% | -28.60% | -9.91% | 6.93% | 74.14% |
| EBIT | 37.67% | -40.94% | -35.41% | -11.39% | 61.18% |
| EBITDA | 28.67% | -25.80% | -17.48% | -0.66% | 45.37% |
| EPS Basic | 115.23% | -27.19% | -7.66% | 3.40% | 65.23% |
| Normalized Basic EPS | 86.20% | -67.49% | -70.97% | -41.90% | 60.54% |
| EPS Diluted | 136.64% | -28.12% | -15.43% | -3.49% | 87.88% |
| Normalized Diluted EPS | 84.41% | -68.47% | -72.06% | -41.83% | 60.33% |
| Average Basic Shares Outstanding | -0.81% | -0.50% | 0.25% | 2.39% | 3.44% |
| Average Diluted Shares Outstanding | 0.49% | 0.34% | 1.07% | 2.59% | 3.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |